Stock TERN TERNS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
5.56 USD -5.12% Intraday chart for Terns Pharmaceuticals, Inc. +2.21% -14.33%
05-08 Terns Pharmaceuticals, Inc. Announces Executive Changes CI
04-29 Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
CI
Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer
CI
North American Morning Briefing : Stocks Struggle After New Records
DJ
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Terns Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity
CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Terns Pharmaceuticals, Inc. Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-ß Agonist TERN-501 in NASH
CI
Terns Pharmaceuticals, Inc. Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session
CI
Terns Pharmaceuticals Q1 Net Loss per Share Narrows
MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
TERNS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Terns Pharmaceuticals Provides Program Updates
CI
TERNS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Terns Pharmaceuticals, Inc. Highlights Results from Phase 1 Clinical Trial of Tern-501 At AASLD The Liver Meeting® 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TERN Stock
  4. News Terns Pharmaceuticals, Inc.
  5. Highlights